COX6A1

Across TCGA pan-cancer cohorts, COX6A1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COX6A1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher COX6A1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated COX6A1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where COX6A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.453	0.260	.012	15	view →
CCRCC	OS	Tertile	All	1.000	0.883	.017	13	view →
GBM	DFS	Quartile	All	0.488	0.233	.002	8	view →
UCEC	DFS	Quartile	III,IV	1.000	0.220	.017	4	view →
HNSC	OS	Median	All	1.000	0.497	.046	4	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COX6A1–PDAC (OS)

Open the PDAC breakdown →